Hongmei Nan1, Teppei Morikawa, Miia Suuriniemi, Yu Imamura, Lillian Werner, Aya Kuchiba, Mai Yamauchi, David J Hunter, Peter Kraft, Edward L Giovannucci, Charles S Fuchs, Shuji Ogino, Matthew L Freedman, Andrew T Chan. 1. Affiliations of authors: Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD (HN); Channing Division of Network Medicine, Department of Medicine (HN, DJH, ELG, CSF, ATC) and Department of Epidemiology (DJH, PK, ELG, SO), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Center for Molecular Oncologic Pathology (TM, YI, AK, MY, SO), Department of Medical Oncology (TM, MS, YI, AK, MY, CSF, SO, MLF), and Department of Biostatistics and Computational Biology (LW), Dana-Farber Cancer Institute, Boston, MA; Department of Epidemiology (DJH, ELG, SO) and Department of Nutrition, Harvard School of Public Health, Boston, MA (DJH, ELG); Broad Institute, Program in Medical and Population Genetics, Cambridge, MA (MLF); Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA (ATC).
Abstract
BACKGROUND: Regular aspirin use reduces the risk for colorectal cancer (CRC), possibly through inhibition of WNT/cadherin-associated protein β1 (CTNNB1 or β-catenin) signaling. The single nucleotide polymorphism (SNP) rs6983267 on chromosome 8q24 is a CRC susceptibility locus that affects binding activity of transcription factor 7 like-2 (TCF7L2) to CTNNB1, thereby altering expression of target oncogenes, including MYC. METHODS: We evaluated regular aspirin use and CRC risk according to genotypes of SNP rs6983267 and CTNNB1 expression status in two prospective case-control studies (840 CRC case patients and 1686 age- and race-matched control subjects) nested within the Nurses' Health Study and the Health Professionals Follow-up Study. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression models. All statistical tests were two-sided. RESULTS: A lower risk of CRC was associated with regular aspirin use and the T allele of rs6983267. The effect of aspirin was confined to individuals with protective T allele of rs6983267 (additive matching factors-adjusted OR for T allele = 0.83; 95% CI = 0.74 to 0.94; P trend = .002; P interaction = .01). Additionally, the T allele of rs6983267 was associated with a reduced expression of MYC oncogene (P trend = .03). Moreover, among individuals with protective T allele, the effect of regular aspirin use was limited to those with positive nuclear CTNNB1 expression. In a functional analysis, in vitro treatment of LS174T cells (a cell line heterozygous for rs6983267) with aspirin was statistically significantly associated with higher G/T allelic ratio of TCF7L2 immunoprecipitated DNA (P = .03). CONCLUSIONS: Our results support an influence of aspirin on WNT/CTNNB1 signaling and suggest that aspirin chemoprevention may be tailored according to rs6983267 genotype.
BACKGROUND: Regular aspirin use reduces the risk for colorectal cancer (CRC), possibly through inhibition of WNT/cadherin-associated protein β1 (CTNNB1 or β-catenin) signaling. The single nucleotide polymorphism (SNP) rs6983267 on chromosome 8q24 is a CRC susceptibility locus that affects binding activity of transcription factor 7 like-2 (TCF7L2) to CTNNB1, thereby altering expression of target oncogenes, including MYC. METHODS: We evaluated regular aspirin use and CRC risk according to genotypes of SNP rs6983267 and CTNNB1 expression status in two prospective case-control studies (840 CRC case patients and 1686 age- and race-matched control subjects) nested within the Nurses' Health Study and the Health Professionals Follow-up Study. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression models. All statistical tests were two-sided. RESULTS: A lower risk of CRC was associated with regular aspirin use and the T allele of rs6983267. The effect of aspirin was confined to individuals with protective T allele of rs6983267 (additive matching factors-adjusted OR for T allele = 0.83; 95% CI = 0.74 to 0.94; P trend = .002; P interaction = .01). Additionally, the T allele of rs6983267 was associated with a reduced expression of MYC oncogene (P trend = .03). Moreover, among individuals with protective T allele, the effect of regular aspirin use was limited to those with positive nuclear CTNNB1 expression. In a functional analysis, in vitro treatment of LS174T cells (a cell line heterozygous for rs6983267) with aspirin was statistically significantly associated with higher G/T allelic ratio of TCF7L2 immunoprecipitated DNA (P = .03). CONCLUSIONS: Our results support an influence of aspirin on WNT/CTNNB1 signaling and suggest that aspirin chemoprevention may be tailored according to rs6983267 genotype.
Authors: Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Gary C Curhan; Charles S Fuchs Journal: JAMA Date: 2005-08-24 Impact factor: 56.272
Authors: Gillian Hawcroft; Mark D'Amico; Chris Albanese; Alexander F Markham; Richard G Pestell; Mark A Hull Journal: Carcinogenesis Date: 2002-01 Impact factor: 4.944
Authors: John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245
Authors: Robert S Sandler; Susan Halabi; John A Baron; Susan Budinger; Electra Paskett; Roger Keresztes; Nicholas Petrelli; J Marc Pipas; Daniel D Karp; Charles L Loprinzi; Gideon Steinbach; Richard Schilsky Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245
Authors: Pamela L Rice; Jennifer Kelloff; Holly Sullivan; Linda J Driggers; K Scott Beard; Scott Kuwada; Gary Piazza; Dennis J Ahnen Journal: Mol Cancer Ther Date: 2003-09 Impact factor: 6.261
Authors: Keming Yang; Xin Li; Michele R Forman; Patrick O Monahan; Bret H Graham; Amit Joshi; Mingyang Song; Dong Hang; Shuji Ogino; Edward L Giovannucci; Immaculata De Vivo; Andrew T Chan; Hongmei Nan Journal: Carcinogenesis Date: 2019-12-31 Impact factor: 4.944
Authors: Xiaoliang Wang; Andrew T Chan; Martha L Slattery; Jenny Chang-Claude; John D Potter; Steven Gallinger; Bette Caan; Johanna W Lampe; Polly A Newcomb; Niha Zubair; Li Hsu; Robert E Schoen; Michael Hoffmeister; Hermann Brenner; Loic Le Marchand; Ulrike Peters; Emily White Journal: Cancer Res Date: 2018-06-19 Impact factor: 12.701
Authors: Hongmei Nan; Carolyn M Hutter; Yi Lin; Eric J Jacobs; Cornelia M Ulrich; Emily White; John A Baron; Sonja I Berndt; Hermann Brenner; Katja Butterbach; Bette J Caan; Peter T Campbell; Christopher S Carlson; Graham Casey; Jenny Chang-Claude; Stephen J Chanock; Michelle Cotterchio; David Duggan; Jane C Figueiredo; Charles S Fuchs; Edward L Giovannucci; Jian Gong; Robert W Haile; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; John L Hopper; Thomas J Hudson; Mark A Jenkins; Shuo Jiao; Noralane M Lindor; Mathieu Lemire; Loic Le Marchand; Polly A Newcomb; Shuji Ogino; Bethann M Pflugeisen; John D Potter; Conghui Qu; Stephanie A Rosse; Anja Rudolph; Robert E Schoen; Fredrick R Schumacher; Daniela Seminara; Martha L Slattery; Stephen N Thibodeau; Fridtjof Thomas; Mark Thornquist; Greg S Warnick; Brent W Zanke; W James Gauderman; Ulrike Peters; Li Hsu; Andrew T Chan Journal: JAMA Date: 2015-03-17 Impact factor: 56.272
Authors: Konrad H Stopsack; Ericka M Ebot; Mary K Downer; Travis A Gerke; Jennifer R Rider; Philip W Kantoff; Lorelei A Mucci Journal: Cancer Causes Control Date: 2018-06-18 Impact factor: 2.506
Authors: Nadine J McCleary; Kaori Sato; Reiko Nishihara; Kentaro Inamura; Teppei Morikawa; Xuehong Zhang; Kana Wu; Mai Yamauchi; Sun A Kim; Yasutaka Sukawa; Kosuke Mima; Zhi Rong Qian; Charles S Fuchs; Shuji Ogino; Jeffrey A Meyerhardt Journal: Clin Cancer Res Date: 2015-10-21 Impact factor: 12.531